Pan Her | List of Frontiers open access articles

Review

Published on 02 Mar 2023

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer

in Pharmacology of Anti-Cancer Drugs

Zihong Wu
Jiamei Wang
Fengming You
Xueke Li
Chong Xiao

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1142087

7,148 views
10 citations

Case Report

Published on 14 Oct 2021

Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant

in Pharmacology of Anti-Cancer Drugs

Zhichao Gao
Junnan Xu
Yan Wang
Jie Wu
Tao Sun

Frontiers in Oncology

doi 10.3389/fonc.2021.715554

4,052 views
4 citations

Original Research

Published on 16 Dec 2021

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer

in Molecular and Cellular Oncology

Yukun Wang
Xiang Yuan
Jing Li
Zhiwei Liu
Xinyang Li
Ziming Wang
Limin Wei
Yuanpei Li
Xinshuai Wang

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2021.785796

7,305 views
10 citations

Case Report

Published on 18 Jan 2024

Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report

in Thoracic Oncology

Junzhu Xu
Bo He
Yunan Wang
Mengjia Wu
Yanyi Lu
Zixuan Su
Shujun Liu
Fengmin Yin
Jian-Guo Zhou
Wei Hu

Frontiers in Oncology

doi 10.3389/fonc.2023.1268260

4,796 views
7 citations

Original Research

Published on 05 Jan 2021

Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method

in Drug Metabolism and Transport

Jinhui Wang
Feifei Chen
Hui Jiang
Jia Xu
Deru Meng
Peiwu Geng
Dapeng Dai
Jingbo Hu
Yunfang Zhou
Quan Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2020.593518

6,669 views
10 citations

Original Research

Published on 21 May 2021

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer

in Women's Cancer

Chaokun Wang
Shuzhen Deng
Jing Chen
Xiangyun Xu
Xiaochen Hu
Dejiu Kong
Gaofeng Liang
Xiang Yuan
Yuanpei Li
Xinshuai Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.616443

5,740 views
16 citations

Review

Published on 05 Apr 2017

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib

in Pathology

Jon Zugazagoitia
Asunción Díaz
Elisabeth Jimenez
Juan Antonio Nuñez
Lara Iglesias
Santiago Ponce-Aix
Luis Paz-Ares

Frontiers in Medicine

doi 10.3389/fmed.2017.00036

8,172 views
11 citations

Original Research

Published on 16 Jun 2023

Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits

in Breast Cancer

Hui Wang
Qiaoyan Liu
Mi Zhang
Juan Zhang
Ran Ran
Yingying Ma
Jiao Yang
Fan Wang
Shujuan He
Xiaoai Zhao

Frontiers in Oncology

doi 10.3389/fonc.2023.1105474

3,892 views
2 citations

Articles

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer

Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer

Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report

Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib

Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits